TY - JOUR
T1 - Antiretroviral therapy at conception in pregnant women with HIV in Italy
T2 - Wide range of variability and frequent exposure to contraindicated drugs
AU - Floridia, Marco
AU - Tamburrini, Enrica
AU - Ravizza, Marina
AU - Anzidei, Gianfranco
AU - Tibaldi, Cecilia
AU - Bucceri, Anna
AU - Maccabruni, Anna
AU - Guaraldi, Giovanni
AU - Meloni, Alessandra
AU - Probizer, Maria Fernanda Ravagni
AU - Guerra, Brunella
AU - Martinelli, Pasquale
PY - 2006
Y1 - 2006
N2 - Methods: Data from a large national surveillance study was used to describe antiretroviral regimens in pregnant women with HIV, with particular reference to the presence at conception of antiretroviral treatments contraindicated in pregnancy. Therapeutic changes during pregnancy were also analysed. Results: Among 334 women on antiretroviral treatment at conception, less than half (42.4%) reported current pregnancy as planned. A large number of different regimens (80) was observed. All the regimens included at least one nucleoside or nucleotide reverse transcriptase inhibitor. Non-nucleoside reverse transcriptase inhibitors and protease inhibitors were present in similar proportions (39.2% and 40.7%, respectively). The most commonly used drugs were lamivudine (83.2% of regimens), zidovudine (50.0%). stavudine (d4T; 38.0%), nevirapine (25.7%), didanosine (ddl; 17.7%) and nelfinavir (17.7%). Treament with efavirenz (13.5% of regimens) and ddl+d4T (9.6%) was markedly frequent. Use of efavirenz at conception was associated with a subsequent treatment change during pregnancy (odds ratio [OR]: 13.2.; 95% confidence interval [CI]: 3.2-53.8, P
AB - Methods: Data from a large national surveillance study was used to describe antiretroviral regimens in pregnant women with HIV, with particular reference to the presence at conception of antiretroviral treatments contraindicated in pregnancy. Therapeutic changes during pregnancy were also analysed. Results: Among 334 women on antiretroviral treatment at conception, less than half (42.4%) reported current pregnancy as planned. A large number of different regimens (80) was observed. All the regimens included at least one nucleoside or nucleotide reverse transcriptase inhibitor. Non-nucleoside reverse transcriptase inhibitors and protease inhibitors were present in similar proportions (39.2% and 40.7%, respectively). The most commonly used drugs were lamivudine (83.2% of regimens), zidovudine (50.0%). stavudine (d4T; 38.0%), nevirapine (25.7%), didanosine (ddl; 17.7%) and nelfinavir (17.7%). Treament with efavirenz (13.5% of regimens) and ddl+d4T (9.6%) was markedly frequent. Use of efavirenz at conception was associated with a subsequent treatment change during pregnancy (odds ratio [OR]: 13.2.; 95% confidence interval [CI]: 3.2-53.8, P
UR - http://www.scopus.com/inward/record.url?scp=33750956541&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750956541&partnerID=8YFLogxK
M3 - Article
C2 - 17302258
AN - SCOPUS:33750956541
VL - 11
SP - 941
EP - 946
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 7
ER -